1215 related articles for article (PubMed ID: 11932270)
1. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
2. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
3. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
[TBL] [Abstract][Full Text] [Related]
4. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
[TBL] [Abstract][Full Text] [Related]
5. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
[TBL] [Abstract][Full Text] [Related]
6. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
Kloos RT; Mazzaferri EL
J Clin Endocrinol Metab; 2005 Sep; 90(9):5047-57. PubMed ID: 15972576
[TBL] [Abstract][Full Text] [Related]
7. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
[TBL] [Abstract][Full Text] [Related]
9. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
10. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?
Robbins RJ; Chon JT; Fleisher M; Larson SM; Tuttle RM
J Clin Endocrinol Metab; 2002 Jul; 87(7):3242-7. PubMed ID: 12107232
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
12. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values.
Kloos RT
J Clin Endocrinol Metab; 2010 Dec; 95(12):5241-8. PubMed ID: 20843945
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
Podoba J
Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
[TBL] [Abstract][Full Text] [Related]
14. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
15. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
20. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin.
Wartofsky L;
Thyroid; 2002 Jul; 12(7):583-90. PubMed ID: 12193302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]